Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review

Zhang, Yujie; Xing, Zhichao; Li, Mi; Li, Zhihui; Zhu, Jingqiang; Tao, Wei; Wu, Wenshuang

doi:10.3389/fonc.2022.929012

Cited by 5 publications

(2 citation statements)

References 84 publications

(105 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While several data on PD-1 blockade in DLBCL-type RS are available, the literature describing this treatment strategy applied to HL-type RS is particularly scarce. Since pembrolizumab has shown notable efficacy in the treatment of de novo R/R HL, a potential therapeutic approach may be represented by this drug [115]. Even though the KEYNOTE-170 (NCT02576990) phase II trial enrolled only two R/R HL-type RS patients, it reported promising efficacy outcomes, with an ORR of 100% (one patient reached a CR and the other achieved a PR) [116].…”

Section: Immune Checkpoint Blockadementioning

confidence: 99%

See 1 more Smart Citation

Immunological Aspects of Richter Syndrome: From Immune Dysfunction to Immunotherapy

Mahmoud

Gaïdano

Mouhssine

2023

Cancers

View full text Add to dashboard Cite

Richter Syndrome (RS) is defined as the development of an aggressive lymphoma in patients with a previous or simultaneous diagnosis of chronic lymphocytic leukemia (CLL). Two pathological variants of RS are recognized: diffuse large B-cell lymphoma (DLBCL)-type and Hodgkin lymphoma (HL)-type RS. Different molecular mechanisms may explain the pathogenesis of DLBCL-type RS, including genetic lesions, modifications of immune regulators, and B cell receptor (BCR) pathway hyperactivation. Limited data are available for HL-type RS, and its development has been reported to be similar to de novo HL. In this review, we focus on the immune-related pathogenesis and immune system dysfunction of RS, which are linked to BCR over-reactivity, altered function of the immune system due to the underlying CLL, and specific features of the RS tumor microenvironment. The standard of care of this disease consists in chemoimmunotherapy, eventually followed by stem cell transplantation, but limited possibilities are offered to chemo-resistant patients, who represent the majority of RS cases. In order to address this unmet clinical need, several immunotherapeutic approaches have been developed, namely T cell engagement obtained with bispecific antibodies, PD-1/PD-L1 immune checkpoint blockade by the use of monoclonal antibodies, selective drug delivery with antibody-drug conjugates, and targeting malignant cells with anti-CD19 chimeric antigen receptor-T cells.

show abstract

Section: Immune Checkpoint Blockadementioning

confidence: 99%

“…Brentuximab vedotin, widely used for the treatment of de novo R/R HL, is a paradigmatic example of the conjugation of an anti-CD30 mAb and an anti-microtubular agent, namely monomethyl auristatin E (MMAE) [115,126].…”

Section: Drug Conjugated Antibodiesmentioning

confidence: 99%

Immunological Aspects of Richter Syndrome: From Immune Dysfunction to Immunotherapy

Mahmoud

Gaïdano

Mouhssine

2023

Cancers

View full text Add to dashboard Cite

show abstract

A new approach for automatic classification of non-Hodgkin lymphoma using deep learning and classical learning methods on histopathological images

Özgür,

Saygılı

2024

Neural Comput & Applic

View full text Add to dashboard Cite

Demyelinating polyneuropathy combined with brachial plexopathy after nivolumab therapy for hodgkin lymphoma: a case report

Park

Kim

2023

BMC Neurol

View full text Add to dashboard Cite

Background Nivolumab is an immune checkpoint inhibitor that targets the programmed cell death-1 protein and is effective in treating advanced cancer. However, it is also associated with various immune-related neurological complications, including myasthenia gravis, Guillain–Barré syndrome, and demyelinating polyneuropathy. These complications can easily mimic other neurological diseases and have greatly varying therapeutic approaches depending on the underlying pathophysiology. Case presentation Here, we report a case of nivolumab-induced demyelinating peripheral polyneuropathy involving the brachial plexus in a patient with Hodgkin lymphoma. Approximately 7 months after nivolumab treatment, the patient experienced muscle weakness with a tightness and tingling sensation in the right forearm. Electrodiagnostic studies showed features of demyelinating peripheral neuropathy with right brachial plexopathy. Magnetic resonance imaging revealed thickening with a diffuse enhancement of both brachial plexuses. The patient was eventually diagnosed with nivolumab-induced demyelinating polyneuropathy involving the brachial plexus. Oral steroid therapy improved motor weakness and sensory abnormalities without aggravation. Conclusion Our study indicates the possibility of nivolumab-induced neuropathies in cases involving muscle weakness with sensory abnormalities of the upper extremity following nivolumab administration in patients with advanced cancer. Comprehensive electrodiagnostic studies and magnetic resonance imaging are helpful in the differential diagnosis of other neurological diseases. Appropriate diagnostic and therapeutic approaches may prevent further neurological deterioration.

show abstract

Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review

Cited by 5 publications

References 84 publications

Immunological Aspects of Richter Syndrome: From Immune Dysfunction to Immunotherapy

Immunological Aspects of Richter Syndrome: From Immune Dysfunction to Immunotherapy

A new approach for automatic classification of non-Hodgkin lymphoma using deep learning and classical learning methods on histopathological images

Demyelinating polyneuropathy combined with brachial plexopathy after nivolumab therapy for hodgkin lymphoma: a case report

Contact Info

Product

Resources

About